Evidence map›Paper›PMID 39702670›Full record

ArticleBone marrow transplantation2025

Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.

Jesús Duque-Afonso, Jürgen Finke, Maud Ngoya, Jacques-Emmanuel Galimard, Johannes Schetelig, Matthias Eder, Wolf Rösler, Gesine Bug, Andreas Neubauer, Matthias Edinger and 12 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [VEXAS syndrome].Zeitschrift fur Rheumatologie · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jesús Duque-AfonsoDepartment of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany. jesus.duque.afonso@uniklinik-freiburg.de.ORCID 0000-0002-8287-5673
Jürgen FinkeDepartment of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany.ORCID 0000-0002-1799-5927
Maud NgoyaEBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France.
Jacques-Emmanuel GalimardEBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France.ORCID 0000-0001-9102-4427
Johannes ScheteligMedical Department I, (Hematology, Oncology and Palliative Care), University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Matthias EderDepartment of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Wolf RöslerDepartment of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany.
Gesine BugDepartment of Medicine 2, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0003-2359-131X
Andreas NeubauerDepartment for Hematology/Oncology and Immunology, University Hospital Giessen and Marburg, Campus Marburg, Philipps Universität Marburg, Marburg, Germany.
Matthias EdingerDepartment of Hematology and Oncology, University of Regensburg, Regensburg, Germany.
Gerald G WulfDepartment of Hematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany.
Pavel JindraDepartment of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.ORCID 0000-0002-8415-7069
Hermann EinseleMedical Department II, University Hospital Wuerzburg, Wuerzburg, Germany.ORCID 0000-0002-7680-0819
Matthias StelljesDepartment of Hematology/Oncology, University of Muenster, Muenster, Germany.
Dominik SelleslagDepartment of Hematology, A.Z. Sint-Jan, Brugge, Belgium.
Eva Maria Wagner-DrouetDepartment of Hematology and Oncology, University Medical Center Mainz, Mainz, Germany.ORCID 0000-0002-0728-2253
Donald BunjesDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Alexandros SpyridonidisDivision of Internal Medicine I, University Hospital of Patras, Patras, Greece.ORCID 0000-0003-3097-2532
Eolia BrissotDepartment of Haematology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.ORCID 0000-0003-4471-418X
Arnon NaglerHematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0002-0763-1265
Fabio CiceriIRCCS San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy.ORCID 0000-0003-0873-0123
Mohamad MohtyDepartment of Haematology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France. mohamad.mohty@inserm.fr.ORCID 0000-0002-7264-808X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols have been developed with the aim of reducing the leukemia burden without increasing their toxicity. We compared the reduced intensity conditioning FM140 (fludarabine, 150 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarmustineHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMelphalanTransplantation ConditioningVidarabineAdultAgedFemaleHumansMaleMiddle AgedRecurrenceRegistriesTransplantation, HomologousCarmustinefludarabineMelphalanVidarabine

Identifiers

PMID39702670
PMCPMC11893469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.